Christopher V DeSIMONE1, David R Holmes1, Elisa Ebrille2, Faisal F Syed3, Dorothy J Ladewig4, Susan B Mikell4, Joanne Powers5, Scott H Suddendorf5, Emily J Gilles4, Andrew J Danielsen4, David O Hodge6, Suraj Kapa1, Samuel J Asirvatham1,7. 1. Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. 2. Division of Cardiology, Department of Medical Sciences, Città della Salute e della Scienza, University of Turin, Italy. 3. Division of Cardiovascular Diseases, University of Michigan, Ann Arbor, Michigan, USA. 4. Mayo Clinic Ventures, Mayo Clinic, Rochester, Minnesota, USA. 5. Division of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota, USA. 6. Department of Health Sciences Research, Mayo Clinic, Jacksonville, Florida, USA. 7. Department of Pediatrics and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Abstract
INTRODUCTION: The dominant location of electrical triggers for initiating atrial fibrillation (AF) originates from the muscle sleeves inside pulmonary veins (PVs). Currently, radiofrequency ablation (RFA) is performed outside of the PVs to isolate, rather than directly ablate these tissues, due to the risk of intraluminal PV stenosis. METHODS: In 4 chronic canine experiments, we performed direct PV muscle sleeve RFA ± postablation drug-coated balloon (DCB) treatment with paclitaxel/everolimus. Of the 4 PVs, 2 PVs were ablated and treated with DCB, 1 PV was ablated without DCB treatment (positive control), and 1 PV was left as a negative control. Local electrograms were assessed in PVs for near-field signals and were targeted for ablation. After 12-14 weeks survival, PVs were interrogated for absence of near-field PV potentials, and each PV was assessed for stenosis. RESULTS: All canines survived the study period without cardiorespiratory complications, and remained ambulatory. In all canines, PVs that were ablated and treated with DCB remained without any significant intraluminal stenosis. In contrast, PVs that were ablated and not treated with DCB showed near or complete intraluminal stenosis. At terminal study, PV potentials remained undetectable. A blinded, histologic analysis demonstrated that ablated PVs without DCB treatment had extensive thrombus, fibrin, mineralization, and elastin disruption. CONCLUSION: Our chronic canine data suggest that direct PV tissue ablation without subsequent stenosis is feasible with the use of postablation DCBs.
INTRODUCTION: The dominant location of electrical triggers for initiating atrial fibrillation (AF) originates from the muscle sleeves inside pulmonary veins (PVs). Currently, radiofrequency ablation (RFA) is performed outside of the PVs to isolate, rather than directly ablate these tissues, due to the risk of intraluminal PV stenosis. METHODS: In 4 chronic canine experiments, we performed direct PV muscle sleeve RFA ± postablation drug-coated balloon (DCB) treatment with paclitaxel/everolimus. Of the 4 PVs, 2 PVs were ablated and treated with DCB, 1 PV was ablated without DCB treatment (positive control), and 1 PV was left as a negative control. Local electrograms were assessed in PVs for near-field signals and were targeted for ablation. After 12-14 weeks survival, PVs were interrogated for absence of near-field PV potentials, and each PV was assessed for stenosis. RESULTS: All canines survived the study period without cardiorespiratory complications, and remained ambulatory. In all canines, PVs that were ablated and treated with DCB remained without any significant intraluminal stenosis. In contrast, PVs that were ablated and not treated with DCB showed near or complete intraluminal stenosis. At terminal study, PV potentials remained undetectable. A blinded, histologic analysis demonstrated that ablated PVs without DCB treatment had extensive thrombus, fibrin, mineralization, and elastin disruption. CONCLUSION: Our chronic canine data suggest that direct PV tissue ablation without subsequent stenosis is feasible with the use of postablation DCBs.
Authors: Hugh Calkins; Karl Heinz Kuck; Riccardo Cappato; Josep Brugada; A John Camm; Shih-Ann Chen; Harry J G Crijns; Ralph J Damiano; D Wyn Davies; John DiMarco; James Edgerton; Kenneth Ellenbogen; Michael D Ezekowitz; David E Haines; Michel Haissaguerre; Gerhard Hindricks; Yoshito Iesaka; Warren Jackman; José Jalife; Pierre Jais; Jonathan Kalman; David Keane; Young-Hoon Kim; Paulus Kirchhof; George Klein; Hans Kottkamp; Koichiro Kumagai; Bruce D Lindsay; Moussa Mansour; Francis E Marchlinski; Patrick M McCarthy; J Lluis Mont; Fred Morady; Koonlawee Nademanee; Hiroshi Nakagawa; Andrea Natale; Stanley Nattel; Douglas L Packer; Carlo Pappone; Eric Prystowsky; Antonio Raviele; Vivek Reddy; Jeremy N Ruskin; Richard J Shemin; Hsuan-Ming Tsao; David Wilber Journal: Heart Rhythm Date: 2012-03-01 Impact factor: 6.343
Authors: George D Dangas; Bimmer E Claessen; Adriano Caixeta; Elias A Sanidas; Gary S Mintz; Roxana Mehran Journal: J Am Coll Cardiol Date: 2010-11-30 Impact factor: 24.094
Authors: M Haïssaguerre; P Jaïs; D C Shah; A Takahashi; M Hocini; G Quiniou; S Garrigue; A Le Mouroux; P Le Métayer; J Clémenty Journal: N Engl J Med Date: 1998-09-03 Impact factor: 91.245
Authors: Kumaraswamy Nanthakumar; Vance J Plumb; Andrew E Epstein; George D Veenhuyzen; Dale Link; G Neal Kay Journal: Circulation Date: 2004-03-01 Impact factor: 29.690
Authors: Prakriti Gaba; Christopher V DeSimone; Benhur D Henz; Paul A Friedman; Charles J Bruce; David R Holmes; Malini Madhavan; Krithika Vasudevan; Douglas Wahnschaffe; Steven Berhow; Andrew J Danielsen; Dorothy J Ladewig; Susan B Mikell; Susan B Johnson; Scott H Suddendorf; Tomas Kara; Gregory A Worrell; Samuel J Asirvatham Journal: J Neurol Neurophysiol Date: 2016-05-25
Authors: Juan J Portero-Portaz; Juan G Córdoba-Soriano; Arsenio Gallardo-López; Jesús M Jiménez-Mazuecos Journal: Eur Heart J Case Rep Date: 2021-11-06